Drug-induced pulmonary disease: an update.
The review provides an update of drug-induced pulmonary disorders, focusing on newer agents whose effects on the lung have been studied recently. Included among these drugs are cyclosporine, cytosine arabinoside (Ara-C), amiodarone, interleukin-2 (IL-2), OKT3, tricyclic antidepressants, and bromocriptine. A brief review of the most common cytotoxic and noncytotoxic agents causing pulmonary toxicity is also included.
Aronchick
J M
JM
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia 19104.
Gefter
W B
WB
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D001971:Bromocriptine / Q000009:adverse effects; D003524:Cyclosporins / Q000009:adverse effects; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects; D008171:Lung Diseases / Q000175:diagnosis*; D050607:Organogold Compounds; D010396:Penicillamine / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D000929:Antidepressive Agents, Tricyclic; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D003524:Cyclosporins; D007376:Interleukin-2; D050607:Organogold Compounds; D001971:Bromocriptine; D010396:Penicillamine